Dedicated to discovery and delivering solutions
As part of its collaborative mission, IBRI has entered into partnership agreements with academic institutions and industry to invest in people and build capabilities that enhance the overall research footprint of the institute.
Cook Medical is the world’s largest private medical device manufacturer, specializing in vascular complications and regenerative medicine.
Corteva Agriscience (formerly Dow AgroSciences) focuses its research and development on innovative chemical and biotechnology solutions to meet the food, feed and fiber needs of the world. The company delivers a broad range of technologies in plant genetics and food production, including agricultural chemicals, biotechnology and germplasm.
Eli Lilly and Company is a global leader in the development of insulin and diabetes medicines and was the first company to make insulin commercially available. The company continues its leadership position by being the first to bring a wide variety of diabetes advancements to market.
Indiana University Health is a statewide system with more than
20 partner hospitals and health centers throughout Indiana. As an academic medical center, IU Health is
associated with Indiana University School of Medicine, one of the nation's largest medical schools and the site of thousands of research projects and clinical trials.
Roche Diagnostics, through a complete test portfolio specific to metabolism, as well as through self-testing solutions for patients, is the market leader in diagnosis and monitoring of diabetes and metabolic disorders.
Regenstrief Institute: Founded in 1969 in Indianapolis, Indiana, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. The Regenstrief Institute and its researchers are responsible for a growing number of major health care innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to the creation of models of care that inform practice and improve the lives of patients around the globe. The Regenstrief Institute is one of the first organizations in the nation to create and use electronic medical records.
The IBRI is nurturing the following 1776 member companies in its lab space.
Adipo Therapeutics is a biotech start-up founded by Purdue Professor Meng Deng, PhD. Adipo is developing a breakthrough technology platform of locally delivered Noth-inhibiting nanoparticles to transform fat, converting energy storing white fat to energy burning brown fat. This new technology has the potential to revolutionize treatment for type 2 diabetes, obesity and cardiovascular disease.
FAST BioMedical is a privately held company based in Indianapolis developing late clinical-stage medical technology. The company’s globally patented technology is the first to directly measure blood volume and kidney function in a clinically actionable way, which has the potential for significant impact on the treatment of patients with heart failure, cardio-renal syndrome, major surgery, sepsis and acute kidney injury. FAST BioMedical has completed four Human Trials in Germany and the United States. These products are investigational and not yet approved for human use.
GenePace Laboratories is an innovative clinical laboratory focused on molecular diagnostics, operating within the IBRI facilities in the 16 Tech Innovation District near Downtown Indianapolis.
Helix BioStructures is a contract research organization providing integrated early drug discovery services to the biopharmaceutical industry. Helix’s core services encompass drug design and development, chemical and structural analysis, protein production and purification, and computational modeling and design.
Xylogenics, Inc. is a synthetic biology company that creates valuable, non-consumed, yeast to enable fermentation based production of natural products. Xylogenics is redefining fermentation, starting with a flagship product for the fuel ethanol market. Xylogenics intends to be at the forefront of the bio-chemical movement creating sustainable solutions for a variety of rapidly expanding markets.